30 closest matches · ranked by relevance
May-Thurner Syndrome · Deep Vein Thrombosis · Chronic Venous Insufficiency
Primary: Safety - Number of Participants Free From Major Adverse Events (MAEs) at 30 Days — 157 Participants
Iliofemoral Venous Obstruction
Primary: Primary Patency — 162 Participants — p=<0.0001
Symptomatic Venous Outflow Obstruction in the Iliofemoral Vein
Primary: Number of Participants With 30-day Freedom From Major Adverse Events — 232 Participants — p=<0.0001
Chronic Venous Disorder · Venous Outflow Obstruction · Symptomatic Venous Outflow Obstruction of Iliofemoral Vein
Primary: Number of Participants With Major Adverse Events (MAE) — 0; 0; 0; 0 Participants
May-Thurner Syndrome
Primary: Left Common Iliac Vein Diameter — 7.5; 7.7 Millimeters (mm)
Chronic Venous Insufficiency
Primary: Safety: AEs, SAEs, ADEs, SADEs, UADEs — 0; 0; 0; 0 Events
Varicose Veins
Primary: Change in Patient-reported Symptoms of Varicose Veins (VVSymQ Score) — 2.13; 4.63; 5.68; 4.87 units on a scale — p==0.0001
Acute Deep Vein Thrombosis
Primary: 2-year Change in Villalta Score — -1.5; -0.5 units on a scale — p=0.34
Chronic Venous Insufficiency
Primary: Mean Change (Reduction) From Baseline in Volume of Reference Leg at Week 16 — 1.13; 5.78 milliliters (mL) — p=0.531
Chronic Venous Insufficiency
Primary: Change in the Quality of Life as Measured by CIVIQ-20 — 12.2 score on a scale
Varicose Veins
Primary: Change in Patient-Reported Symptoms of Varicose Veins (VVSymQ Score) — -2.00; -5.34; -6.01; -5.06 units on a scale — p=<0.0001
Venous Thromboembolism · Venous Thrombosis
Primary: Number of Patients With Asymptomatic Venous Thrombosis of Lower Limbs as Detected by Duplex Ultrasound — 1; 34 Participants — p=<0.001
Vascular Malformations · Vascular Malformation Peripheral · Venous Malformation
Primary: Volume Difference of Malformation to Baseline (no Compression) While Wearing Compression Stockings Class I and II Determined by MRI — 16.38; 23.7 ml
Venous Thrombosis
Primary: Change in Femoral Venous Peak Flow Velocity Compared to Resting Baseline — 18.9 cm/s — p=<0.0001
Coronary Bypass Graft Stenosis of Autologous Vein
Primary: Early Complications of Vascular Zone — 1; 4; 15; 5 participants — p=0.05
Deep Vein Thrombosis · Venous Thrombosis · Postphlebitic Syndrome
Primary: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) — 157; 171 Participants — p=0.56
Varicose Veins
Primary: The Absolute Change From Baseline Score for the VVSymQ (Total Score) at 8 Weeks — 16.7; 30.7 units on a scale
May-Thurner Syndrome · Peripheral Vascular Disease · Venous Disease
Primary: Number of Participants With Primary Patency of the Venous Stent at 12 Months Post-Index Procedure — 128 Participants — p=0.0001
Deep Venous Thrombosis
Primary: Incidence of Post-thrombotic Syndrome (PTS) — 44; 37 participants — p=.58
Deep Vein Thrombosis · Post-thrombotic Syndrome
Primary: Change From Baseline in Villalta Score at Day 30 Post-EkoSonic® Study Treatment Procedure — 15.5; -5.9 units on a scale
Varicose Veins
Primary: Rate of Re-do Surgery — 15; 38 legs
Chronic Venous Insufficiency
Primary: Vein Occlusion Rate — 29; 0; 0 limbs
Surgical Wound
Primary: Time to Ambulation (TTA) — 2.8; 6.1 hours
Coronary Heart Disease
Primary: Brachial Flow Velocity — 21.0 cm/sec
Deep Vein Thrombosis Leg · DVT · Chronic DVT of Lower Extremity
Primary: Primary Safety Endpoint: Proportion Participants With Major Adverse Events — 15 Participants
Venous Thrombosis · Deep Vein Thrombosis
Primary: Rate of Deep Vein Thrombosis — 14; 15; 9; 12 participants — p=0.785
Venous Thrombosis
Primary: The Primary Effective Endpoint: Percent of Treated Vessel(s) With ≥ 75% Venous Thrombus Reduction in Modified Marder Score (From Pre-JETi to Final) — 84.5 percentage of…
Venous Leg Ulcer
Primary: Change From Baseline in Wound Perimeter — 29.36; 43.64 mm
Great Saphenous Vein Incompetence · Visible Varicosities
Primary: Absolute Change From Baseline in Independent Photography Review (IPR-V3 Score) — -0.80; -1.30; -1.11 score
Venous Insufficiency
Primary: Primary Effectiveness Objective — 53; 66 Treated IPVs